Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer

Journal of the Pancreas

Volumn 15, Issue 2, 2014, Pages 91-94

  Chandhok, Namrata Sonia ^a   Saif, Muhammad Wasif ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug therapy; General surgery; Pancreatic neoplasms; S 1 (combination)

Indexed keywords

CAPECITABINE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; CANCER MORTALITY; CONFERENCE PAPER; HEALTH CARE PLANNING; HUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

EID: 84897882424     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2303     Document Type: Conference Paper

References (20)

1. Surveillance, Epidemiology and End Results program. Available at: http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed January 30, 2014.
2. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-17.
3. Gillen S, Schuster T, Meyerzum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.
4. NCCN Guidelines. Pancreatic Cancer. Available at: http://www.tri-kobe.org/NCCN/guideline/pancreas/english/pancreatic.Accessed January 30, 2014.
5. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-56.
6. Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and unresectable pancreatic cancer. Ann Oncol. 2013;24(10):2484-92.
7. Von hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;:131016140055001-.
8. Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;365(8):768-9.
9. Mizuma M, Motoi F, Fujishima F et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: A prospective, multi-institutional, phase II trial. Multidisciplinary Treatment 283 J Clin Oncol 32, 2014 (suppl 3; abstr 283)
10. Hattori M, Fujii T, Suenaga M, et al. Neoadjuvant chemoradiotherapy with S-1 in patients with borderline resectable pancreatic cancer. Multidisciplinary Treatment 302 J Clin Oncol 32, 2014 (suppl 3; abstr 302)
11. McCormick K, Whiting S, Gyurkey G, et al. Long-term survival of patients receiving multimodality neoadjuvant therapy for resectable or borderline resectable pancreatic ductal adenocarcinoma. Multidisciplinary Treatment. J Clin Oncol 32, 2014 (suppl 3; abstr 309)
12. Gulati AP, Schreibman S, Schrope B, et al. Prospective phase II study of inoperable pancreatic adenocarcinoma with neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX). Multidisciplinary Treatment 274 J Clin Oncol 32, 2014 (suppl 3; abstr 274)
13. Blazer MA, Wu C, Goldberg R. Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC). Multidisciplinary Treatment 275 J Clin Oncol 32, 2014 (suppl 3; abstr 275)
14. Son CO, Pai S., Satti S et al. Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: Singleinstitution experience. Multidisciplinary Treatment 327 J Clin Oncol 32, 2014 (suppl 3; abstr 327)
15. Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist. 2008;13(3):261-76.
16. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10(20):6956-61.
17. Giovannetti E, Deltacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66(7):3928-35.
18. Morinaga S, Nakamura Y, Watanabe T, et al. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol. 2012;19 Suppl 3:S 558-64.
19. Miyoshi K, Sato N, Ohuchida K, Mizumoto K, Tanaka M. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res. 2010;30(3):867-71.
20. Arnold SA, Rivera LB, Miller AF, et al. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech. 2010;3(1-2):57-72.